US 12,064,437 B2
Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies
Peter H. Schafer, Belle Mead, NJ (US); and Shaojun Tang, Summit, NJ (US)
Assigned to CELGENE CORPORATION, Summit, NJ (US)
Filed by CELGENE CORPORATION, Summit, NJ (US)
Filed on Sep. 30, 2021, as Appl. No. 17/490,778.
Claims priority of provisional application 63/087,008, filed on Oct. 2, 2020.
Prior Publication US 2022/0160720 A1, May 26, 2022
Int. Cl. A61K 31/5377 (2006.01); A61P 37/00 (2006.01); C12Q 1/6883 (2018.01)
CPC A61K 31/5377 (2013.01) [A61P 37/00 (2018.01); C12Q 1/6883 (2013.01); C12Q 2600/158 (2013.01)] 18 Claims
 
1. A method of determining a dose of a treatment compound for treating a subject having systemic lupus erythematosus (SLE), comprising:
(a) measuring the gene expression level of IKZF3 in a sample from the subject; and
(b) determining the dose of the treatment compound to be 0.45 mg or higher per day if a score calculated based on the gene expression level of IKZF3 in the sample is higher than a reference level,
wherein the treatment compound is a compound of Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.